The psoriatic arthritis treatment market size in 2026 comprises medicines used to manage the symptoms and progression of this inflammatory condition. Treatment options include conventional disease-modifying antirheumatic drugs, biologic therapies, targeted synthetic medicines, and other medications used to address pain and inflammation. The selection of treatment depends on disease severity, affected joints, previous treatment response, and individual patient requirements. Growing awareness of the condition and developments in immunology are contributing to the expansion of available therapeutic options.
According to Fortune Business Insights, the global psoriatic arthritis treatment market size was valued at USD 12.59 billion in 2025 and is projected to grow from USD 13.97 billion in 2026 to USD 32.11 billion by 2034, exhibiting a CAGR of 10.96% during the forecast period. North America dominated the psoriatic arthritis treatment market with a market share of 43.78% in 2025. Psoriatic arthritis is a chronic inflammatory condition associated with psoriasis that can affect joints, tendons, and surrounding tissues. Treatment aims to control inflammation, reduce pain and stiffness, manage disease activity, and help prevent long-term joint damage.
Major companies operating in the global psoriatic arthritis treatment market include:
Increasing Diagnosis and Demand for Long-Term Disease Management
Growing recognition of psoriatic arthritis and its relationship with psoriasis is supporting demand for treatment. The condition can involve joint pain, swelling, stiffness, and inflammation in other parts of the musculoskeletal system. Improved awareness among patients and healthcare professionals can encourage earlier medical evaluation and help patients access appropriate treatment. Since psoriatic arthritis is a chronic condition, many patients require ongoing monitoring and treatment adjustments, contributing to sustained demand for medicines.
Development of Biologic and Targeted Therapies